TAMPA, Fla., Feb. 2, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced that the U.S Food and Drug Administration's (FDA)...
Hence then, the article about tuhura biosciences received fda orphan drug designation for ifx 2 0 for the treatment of stage iib to stage iv cutaneous melanoma was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( TuHURA Biosciences received FDA Orphan Drug Designation for IFx-2.0 for the Treatment of Stage IIB to Stage IV Cutaneous Melanoma )
Also on site :
- HBO Max Moves Up Forthcoming Episodes Of ‘Industry,’ ‘A Knight Of The Seven Kingdoms’ Ahead Of Super Bowl
- Islamic State claims Niger airport attack
- Donald Trump Slams Grammys as ‘Unwatchable’ and Calls Trevor Noah a ‘Total Loser’ Over Trump-Epstein Island Joke: ‘It Looks Like I’ll Be Sending My Lawyers to Sue This Pathetic Dope’